Price
$2.14
Decreased by -0.23%
Dollar volume (20D)
25.71 K
ADR%
6.15
Earnings report date
Sep 17, 2025
Shares float
59.22 M
Shares short
52.01 K [0.09%]
Shares outstanding
92.17 M
Market cap
197.93 M
Beta
0.93
Price/earnings
N/A
20D range
1.70 2.63
50D range
1.70 2.63
200D range
1.29 3.51

Innate PharmaS. A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.

The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited.

Innate PharmaS. A. was incorporated in 1999 and is based in Marseille, France.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 13, 25 0.00
Decreased by N/A%
-
Mar 27, 25 -0.30
Decreased by N/A%
-0.40
Increased by +25.00%
Nov 13, 24 0.00
Decreased by N/A%
-
Sep 12, 24 0.00
Decreased by -100.00%
-0.38
Increased by +100.00%
May 14, 24 0.00
Decreased by N/A%
-
Mar 21, 24 0.00
Decreased by N/A%
-0.41
Increased by +100.00%
Nov 14, 23 0.00
Decreased by N/A%
-
Sep 14, 23 0.02
Increased by +N/A%
-0.14
Increased by +114.29%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 276.00 K
Decreased by -97.43%
-24.71 M
Decreased by -432.02%
Decreased by -8.95 K%
Decreased by -20.57 K%
Jun 30, 24 12.35 M
Decreased by -65.07%
-24.76 M
Decreased by -1.54 K%
Decreased by -200.60%
Decreased by -4.23 K%
Mar 31, 24 21.44 M
Increased by +6.69%
-9.29 M
Decreased by -1.18 K%
Decreased by -43.31%
Decreased by -1.11 K%
Dec 31, 23 21.44 M
Increased by +158.07%
-9.29 M
Increased by +85.58%
Decreased by -43.31%
Increased by +94.41%
Sep 30, 23 10.72 M
Increased by +77.43%
-4.64 M
Increased by +85.57%
Decreased by -43.31%
Increased by +91.87%
Jun 30, 23 35.34 M
Decreased by -14.36%
1.72 M
Decreased by -72.74%
Increased by +4.86%
Decreased by -68.17%
Mar 31, 23 20.10 M
Increased by +N/A%
859.00 K
Increased by +N/A%
Increased by +4.27%
-
Dec 31, 22 8.31 M
Increased by +197.49%
-64.41 M
Decreased by -121.40%
Decreased by -775.14%
Increased by +25.58%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY